Q-omics provides the consensus-scored ZNF56 profile across patient tissues and cancer cell-line models. ZNF56 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF56 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZNF56 RNA expression shows 21,260 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KICH, and ACC as cancer lineages where ZNF56 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF56 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF56 survival associations across molecular data types. ZNF56 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF56 RNA expression–survival associations across cancer types. High ZNF56 expression shows unfavorable associations in ACC, but favorable associations in BRCA, PAAD, MESO, HNSC and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF56 RNA expression.
This table summarizes ZNF56 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF56. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF56 shows lower tumor expression in KICH, THCA, LUAD and BRCA and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher ZNF56 RNA expression in normal versus tumor tissue (log2 FC = −0.789, t-test p < 0.001).
This table shows molecular features associated with ZNF56 in patient tissues and cancer cell lines. In patient samples, ZNF56 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
